Freedom of Information Act 2000 – Request Reference FoI/24/045
Hidradenitis Suppurativa and Giant Cell Arteritis

Q1. Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Bimekizumab
- Certolizumab
- Infliximab
- Secukinumab
- Ustekinumab

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within Regulations for responding to a request. The UHB has therefore relied upon the section 12 exemption of the Freedom of Information Act 2000 ('Exemption where cost of compliance exceeds appropriate limit') and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within Regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the Fees Regulations for this amount of work (18 hours) is £450 for the UHB. The Fees Regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

Q2. In the past 3 months, how many patients with a primary diagnosis of giant cell arteritis (ICD10 codes M31.5 or M31.6) were:

- Admitted as an inpatient

There was one patient admitted from 1 October 2023 to 31 December 2023 where the primary diagnosis code is M31.5 or M31.6.

Please note, however, that data for the same three-month period in 2022 provides a slightly greater number of patients. This *may* suggest that the current figures appear artificially lower due to a delay in coding.

- Treated in A&E

The UHB does not hold this information. As these codes do not apply to A&E data, no such search could be conducted.

Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:

- Tocilizumab – for any disease – 96
- Tocilizumab for rheumatoid arthritis (RA) only
- Tocilizumab for giant cell arteritis (GCA) only

The UHB believes the section 12 exemption to apply for your requests for RA and GCA data and is therefore refusing your request.

Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?

Zero patients.

Q5. How many patients were treated in A&E in the past 3 months (for any disease) with Tocilizumab?

Zero patients.